Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide is a synthetic small molecule belonging to the isoquinolines and derivatives class. It is primarily used as a potent and selective inhibitor of casein kinase I (CK1), with much weaker activity against casein kinase II (CK2) and other protein kinases. The compound acts by inhibiting the ATP-binding site of CK1, thereby blocking its kinase activity. This molecule is mainly utilized in biochemical research to study protein phosphorylation pathways involving casein kinases[4][5]. It has not been approved for clinical use or therapeutic indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide.